Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ACR | P10323 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6819585 | 0.87 | CNR2 (0.52) | CNR2RAB9ANPC1MAPTTHRB | |
| SCHEMBL6833874 | 0.86 | RAB9A (0.50) | CNR2RAB9ANPC1MAPTTHRB | |
| SCHEMBL6818402 | 0.81 | RAB9A (0.48) | CNR2RAB9ANPC1MAPTTHRB | |
| SCHEMBL6817788 | 0.81 | CNR2 (0.55) | CNR2RAB9ANPC1MAPTTHRB | |
| SCHEMBL6819417 | 0.80 | MAPT (0.46) | CNR2RAB9ANPC1MAPTTHRB | |
| SCHEMBL22619918 | 0.79 | RAB9A (0.67) | RAB9ANPC1MAPTTHRBALDH1A1 | |
| SCHEMBL6818513 | 0.79 | MAPT (0.54) | CNR2RAB9ANPC1MAPTTHRB | |
| SCHEMBL6818861 | 0.78 | CNR2 (0.52) | CNR2RAB9ANPC1MAPTTHRB | |
| SCHEMBL6818863 | 0.77 | CNR2 (0.59) | CNR2RAB9ANPC1MAPTTHRB | |
| SCHEMBL6817480 | 0.76 | CNR2 (0.54) | CNR2RAB9ANPC1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | CNR2 3495/4885RAB9A 4337/4885NPC1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.